Scarica l'app Stockscreener
106.87
0.90%
0.95
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Incyte Corporation Stock Live Price, Chart, Analysis, News & Forecast – Buy, Sell & Trade US Equities Today - livemint.com
Incyte jumps amid takeover speculation - MSN
Bull of the Day: Eli Lilly (LLY) - Finviz
Can Incyte Corporation stock reach $100 price targetExit Point & Scalable Portfolio Growth Methods - ulpravda.ru
Why Incyte Corporation (ICY) stock is a strong buy callGap Down & Expert Approved Momentum Ideas - ulpravda.ru
Can Incyte Corporation stock beat market expectations this quarter2025 Macro Impact & Low Volatility Stock Recommendations - ulpravda.ru
Can Incyte Corporation stock hit analyst price targets2025 Key Lessons & Safe Entry Momentum Stock Tips - ulpravda.ru
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Incyte Corp EVP & Chief Medical Officer Sells 15,634 Shares - TradingView — Track All Markets
Incyte (INCY) Stock Is Up, What You Need To Know - Finviz
Incyte eyes first-line nod for Tafasitamab in aggressive lymphoma - Indian Pharma Post
Incyte stock hits 52-week high at $109.38 - Investing.com
INCY: Morgan Stanley Boosts Price Target to $94 in Latest Analys - GuruFocus
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Dow, S&P 500 Hit Record Highs; Guardant, Intuitive Surgical, Incyte In Focus - Investor's Business Daily
Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins (NASDAQ:INCY) - Seeking Alpha
INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma - Finviz
Incyte's Monjuvi poised for first-line DLBCL expansion after pivotal study win - FirstWord
Incyte (NASDAQ:INCY) Price Target Raised to $94.00 - MarketBeat
Incyte reports positive results in late stage trial of lymphoma drug - Delaware Business Now
Positive top-line results for Incyte’s tafasitamab in DLBCL - The Pharma Letter
Spotlight On: Incyte's win in first-line DLBCL points to incremental growth opportunity for Monjuvi - FirstWord
Incyte stock rises as Stifel reiterates Buy rating on positive trial data - Investing.com India
Why Is Incyte Stock Gaining Monday?Incyte (NASDAQ:INCY) - Benzinga
Incyte's blood cancer therapy slows disease progression in trial - Reuters
The Bull Case For Incyte (INCY) Could Change Following Positive frontMIND Phase 3 DLBCL Results - simplywall.st
Incyte (INCY) Achieves Phase 3 Success with Tafasitamab in Lymph - GuruFocus
Incyte marks late-stage trial win for Xencor-partnered lymphoma therapy - Seeking Alpha
Incyte’s tafasitamab meets primary endpoint in frontMIND trial By Investing.com - Investing.com Canada
Incyte (INCY) Achieves Key Milestones in Phase 3 Lymphoma Study - GuruFocus
Incyte’s tafasitamab meets primary endpoint in frontMIND trial - Investing.com
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi - Business Wire
Incyte Corp (NASDAQ:INCY) Shows High-Growth Momentum and Strong Technical Trend - Chartmill
Financiere des Professionnels Fonds d investissement inc. Invests $1.48 Million in Incyte Corporation $INCY - MarketBeat
Incyte Corp. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
INCYTE CORPORATION CMNRo Khanna Congressional Trade on May. 02, 2017 - Quiver Quantitative
Incyte takes JPMorgan stage as investors look for pipeline signals - MSN
Incyte Takes JPMorgan Stage as Investors Look for Pipeline Signals - MyChesCo
Incyte Corporation (NASDAQ:INCY) Receives Average Rating of "Hold" from Analysts - MarketBeat
Europe Approves Incyte’s Dual-Target Lymphoma Therapy, Expanding Options - MyChesCo
22,200 Shares in Incyte Corporation $INCY Purchased by Burney Co. - MarketBeat
Incyte Corporation (INCY) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Pacer Advisors Inc. Grows Position in Incyte Corporation $INCY - MarketBeat
Swedbank AB Decreases Stock Holdings in Incyte Corporation $INCY - MarketBeat
Is It Too Late To Consider Incyte After A 45% Rally In 2025? - Yahoo Finance
Incyte Board Exit Closes an Era for the Biotech’s Longtime Leader - MyChesCo
Incyte (INCY) Valuation Check After Japan Oncology Approvals for Minjuvi and Zynyz - simplywall.st
The Bull Case For Incyte (INCY) Could Change Following New Minjuvi And Zynyz Approvals In Europe And Japan - Yahoo Finance
Thomas Tray Sells 600 Shares of Incyte (NASDAQ:INCY) Stock - MarketBeat
Incyte (NASDAQ:INCY) Insider Sells $277,400.00 in Stock - MarketBeat
Incyte principal accounting officer Tray Thomas sells shares worth $336k - Investing.com
Incyte Corp Principal Accounting Officer Sells Shares - TradingView — Track All Markets
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Incyte (NASDAQ:INCY) Stock Price Down 3.4%Time to Sell? - MarketBeat
Incyte Secures Dual Approvals In Japan For Zynyz And Minjuvi - RTTNews
Incyte (INCY) Soars 5.5%: Is Further Upside Left in the Stock? - Yahoo Finance
Japan Approves Incyte’s (NASDAQ:INCY) Zynyz for First-Line Anal Cancer - Kalkine Media
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalido - PharmiWeb.com
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer - PharmiWeb.com
Japan Approves Incyte's (INCY) Zynyz for First-Line SCAC Treatme - GuruFocus
1.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):